EVALUATING HLA CLASS II EVOLUTIONARY DIVERGENCE AS AN IMMUNOTHERAPY-SPECIFIC KIDNEY CANCER BIOMARKER

$1,198,458FY2021Defense Health AgencyDOD

Sloan-Kettering Institute For Cancer Research

Investigators